Core Viewpoint - The company, Xiansheng Pharmaceutical (02096.HK), has entered into a placement and subscription agreement to issue 121 million shares at a price of HKD 12.95 per share, which represents an approximate 8.03% discount from the last closing price of HKD 14.08 [1][2]. Group 1: Placement and Subscription Details - The seller, Simcere Pharmaceutical Holding Limited, holds approximately 938 million shares, accounting for about 37.92% of the company's total issued shares [2]. - The total estimated gross proceeds from the subscription are approximately HKD 1.567 billion, with a net amount of about HKD 1.554 billion expected to be received by the company [2]. - The placement shares represent about 4.89% of the company's total issued shares as of the announcement date, and the enlarged total issued shares after the placement will be approximately 4.66% [1]. Group 2: Use of Proceeds - Approximately 90% of the net proceeds will be allocated to research and development expenses, which include accelerating clinical research for new drugs in China and the U.S., and supporting the expansion of approved innovative drugs into new indications [2]. - The remaining 10% of the net proceeds will be used for working capital and other general corporate purposes to support the company's daily operations and long-term development needs [2].
先声药业(02096.HK)拟先旧后新配股总筹15.67亿港元 创新药研发加速